RetiredUnitedHealthcarePolicy CS151LA.I

Reproductive Carrier Genetic Screening and Genetic Counseling

Defines medical policy coverage and criteria for genetic counseling and reproductive carrier screening panels for members covered under Louisiana Medicaid Managed Care; applies to providers ordering and documenting testing for reproductive carrier screening and associated counseling.

Policy Summary

PayerUnitedHealthcare

PolicyReproductive Carrier Genetic Screening and Genetic Counseling

Policy CodePolicy CS151LA.I

Change TypeRetirement / informational update

Effective DateOct 1, 2025

Next Review Date

Key ActionVerify benefit plan coverage and any prior authorization requirements per plan terms before ordering expanded carrier screening; document genetic counseling and family history in the medical record.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

up to 6 genesMedically necessary (basic)

up to 15 genesMedically necessary (with risk)

16+ genesNot medically necessary

LouisianaApplies to state

63% carriersDetection (37 vs 176)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

39%ECS uptake (literature)

Coverage criteria for reproductive carrier screening

Medically Necessary Panel Criteria

Covered when ALL of the following are met (by panel size/risk rules):

Basic panels (up to 6 genes): Reproductive Carrier Screening Panels of up to six genes are proven and medically necessary.<=6 genes

Covered for general use.

Intermediate panels (up to 15 genes) with risk: Reproductive Carrier Screening Panels of up to 15 genes are proven and medically necessary when the individual and/or their reproductive partner have Ashkenazi Jewish ancestry OR a biological first- or second-degree relative affected by one or more of the conditions evaluated by the panel.<=15 genes AND (Ashkenazi Jewish ancestry OR affected first/second-degree biological relative)

State-specific criteria per Louisiana Medicaid.

Exclusions: Reproductive Carrier Screening Panels comprised of 16 or more genes are unproven and not medically necessary.>=16 genes

Claims for such panels may be denied.

Panel size and carrier-frequency threshold considerations

Evidence relevant to panel composition and thresholds

Conservative vs liberal carrier-frequency thresholds: Analysis of 460,608 individuals found 37 conditions met conservative thresholds (e.g., carrier frequency ≥1/100) and 74 met more liberal thresholds (≥1/200); a 37-condition panel would detect 63% of carriers and 84.6% of at-risk couples compared with a 176-condition panel.carrier frequency >=1/100 (conservative) or >=1/200 (liberal)

Panels aligned with ACOG/ACMG guideline thresholds could be achieved with either threshold set.

Comparative detection performance

Comparative performance and equity

ECS vs ethnicity-based screening: Multiple studies report that expanded carrier screening (ECS) identifies substantially more carriers and carrier couples than ethnicity-based or ACOG-based ethnicity screening; in one cohort ECS identified 29.4% carriers versus 8.5% for ethnicity-based and 15.6% for ACOG-based screening. Self-reported ethnicity is an imperfect predictor of genetic ancestry and can lead to missed carriers, creating inequitable detection across populations.n/a

Supports population-neutral or pan-ethnic screening approaches.

Operational considerations

Implementation impact and workflow considerations

Counseling and workflow burden: Genomic- or large-panel ECS increases genetic counselor workload and preparation time (median 64 minutes per positive follow-up in one study) and may generate many findings of uncertain immediate reproductive relevance; some participants became pregnant before result disclosure, increasing time-sensitivity and potential clinical impact.n/a

Highlights resource, access, and timing concerns when implementing large-genomic panels.

Guideline-based offering logic

Professional society recommendations summarized (not explicit UnitedHealthcare coverage criteria in this excerpt):

ACOG universal offers: Offer hemoglobinopathy testing to all individuals planning pregnancy or at the first prenatal visit if not previously tested; offer carrier screening for cystic fibrosis (CF) and spinal muscular atrophy (SMA) to all individuals who are pregnant or considering pregnancy. If ECS is considered, panels should generally include conditions with carrier frequency >1/100, well-defined phenotypes, early onset, and exclude adult-onset conditions.

ACOG Practice Advisory and Committee Opinions cited.

ACMG tiered approach: ACMG recommends a tiered system: Tier 1 (CF + SMA + risk-based), Tier 2 (≥1/100), Tier 3 (≥1/200 including X-linked) which should be offered to all pregnant/planning patients, and Tier 4 (<1/200) reserved for consanguinity or specific family/history indications.

Promotes population-neutral paradigms and offering Tier 3 broadly.

NSGC recommendation: NSGC conditionally recommends offering ECS to all individuals considering reproduction, pregnant individuals, and their partners, using shared decision-making; the recommendation is conditional with low-to-moderate certainty and emphasizes addressing barriers such as insurance coverage and access to genetics professionals.

Reproductive Carrier Screening Panels that include 16 or more genes are considered unproven and not medically necessary due to insufficient evidence of clinical efficacy.

This excerpt does not list any explicit test exclusions; published studies demonstrate wide variability in which specific conditions and genes are included across commercial panels, with panel sizes in reviewed studies ranging from small gene sets (e.g., 3–23 genes) up to global panels assessing hundreds of diseases.

The Royal College of Obstetricians and Gynaecologists (RCOG) states there is insufficient evidence to recommend routine testing of all prospective parents; RCOG also emphasizes the lack of standardization among expanded carrier screening panels and that interpretation should be performed by clinicians with appropriate genetics expertise.

Carrier screening performed outside the policy-specified panel sizes and risk-based criteria — i.e., testing beyond the covered panels — is considered unproven and not medically necessary.

Expanded carrier screening can increase detection but may also cause potential harms including increased counseling burden, patient anxiety, and misunderstanding of reproductive risk. The literature notes limited evidence directly comparing outcomes from minimal guideline-based panels versus expanded panels, and that large panels may identify findings of uncertain reproductive relevance which can increase clinical workload and interpretation complexity.

Procedure and code references

Applicable Procedure Codes (reference)CPT

0400U	Obstetrics (expanded carrier screening), 145 genes by next generation sequencing, fragment analysis and multiplex ligation dependent probe amplification, DNA, reported as carrier positive or negative.
81412	Ashkenazi Jewish associated disorders, genomic sequence analysis panel, must include sequencing of at least 9 genes (e.g., ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, SMPD1).
81443	Genetic testing for severe inherited conditions, genomic sequence analysis panel, must include sequencing of at least 15 genes (e.g., ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH).
81479	Unlisted molecular pathology procedure

Carrier frequency thresholds for panel inclusion

ACOG suggested thresholdInclude conditions with carrier frequency ≥1/100 (correlates with disease incidence ~1/40,000).

ACMG tier-based thresholdACMG Tier 3 includes conditions with carrier frequency ≥1/200 (includes X-linked; recommended to be offered to all pregnant/planning patients).

Conservative vs. liberal panel examplesStudy of 460,608 individuals: 37 conditions met conservative (≥1/100) and 74 met liberal (≥1/200) thresholds; panels using either threshold can align with guidelines.

Actions, documentation, and billing considerations for providers

Prior Authorization

Authorization & Plan Governance

No explicit prior authorization or claims-denial triggers are specified in this policy excerpt. However, before ordering expanded carrier screening or related genetic testing, providers must verify member benefits and any plan-specific prior authorization requirements.

Verify benefits and any prior authorization requirements per the enrollee's federal, state, or contractual benefit plan before ordering testing.
This policy is informational and does not itself establish coverage; the member's plan/contract governs coverage determinations and prevails in case of conflict.

Documentation Required

Required Genetic Counseling Documentation

Genetic counseling is required both before and after genetic testing. Documentation in the medical record must include all of the following elements: a structured family genetic history, a genetic risk assessment, and counseling of the enrollee and family about diagnosis, prognosis, and treatment.

Background and rationale

Carrier screening is genetic testing of an asymptomatic individual to determine whether they carry variants that could place biological children at risk of autosomal recessive or X-linked conditions. Results can inform reproductive decision-making, including use of partner testing, preimplantation genetic testing, or prenatal planning.

Definitions used in this policy

Carrier Screening (definition)

DefinitionGenetic testing performed on an asymptomatic individual to determine whether they carry a variant associated with disorders that could be passed to biological children (ACOG, 2017a, reaffirmed 2023).

PurposeIdentify carrier status to inform reproductive decision-making and risk assessment for offspring.

ContextPerformed in individuals who are pregnant or considering pregnancy; may be pan-ethnic or ancestry-based.

First‑Degree Relative

DefinitionIncludes parents, siblings, and children (First‑Degree Relatives).

UsageUsed when assessing family history to determine eligibility for expanded panels or targeted testing.

Policy Summary

PayerUnitedHealthcare

PolicyReproductive Carrier Genetic Screening and Genetic Counseling

Policy CodePolicy CS151LA.I

Change TypeRetirement / informational update

Effective DateOct 1, 2025

Next Review Date

SourceLink

On This Page

Offers ECS as an alternative to ethnicity-based screening.

RCOG cautions: RCOG indicates insufficient evidence to recommend routine testing of all prospective parents, notes lack of standardization among ECS panels, and emphasizes the need for clinicians with genetics expertise for interpretation and careful selection of panel content.

Highlights variability among panels and limited routine endorsement.

Document structured family genetic history in the medical record.
Document genetic risk assessment.
Document counseling provided to the enrollee and family regarding diagnosis, prognosis, and treatment.

Documentation Required

Ethnicity and Ancestry Documentation Considerations

Collect and document self-reported ethnicity and the method used to obtain it. Note that self-reported ethnicity may differ from genetic ancestry; where genetic ancestry is relevant to testing decisions, document the source and any limitations of the ethnicity/ancestry information.

Record the method used to collect ethnicity (e.g., patient interview, test requisition form, family-history intake).
If genetic ancestry data are used or available, document how ancestry was determined and any discrepancies with self-reported ethnicity.

Billing Rule

Documentation & Benefit Verification

Providers must check applicable federal, state, and contractual benefit plan language for coverage rules and any additional documentation required to support medical necessity. Maintain documentation to support the clinical rationale for testing in the medical record.

Reference federal, state, or contractual requirements when determining coverage.
Document clinical rationale and any supporting medical necessity evidence in the medical record.
Confirm whether specific procedure codes are covered under the member's plan prior to billing.

Denial Risk

Denial Risk for Large Panels

Panels of 16 or more genes are considered unproven and not medically necessary in this policy and may be at higher risk for denial; prefer smaller panels per policy criteria and document justification if ordering larger panels under special circumstances.

Reproductive carrier screening panels of up to 6 genes are supported; up to 15 genes are supported when ancestry or family-history criteria are met.
Panels of 16+ genes are considered unproven and not medically necessary and may be denied.

ReferenceDefined per NCCN (2024) in policy definitions.

Gene Panel

DefinitionTesting panels that look for genetic changes/variants in more than one gene in the same test.

ScopeCan range from small (≤6 genes) to large expanded panels (dozens to thousands of genes); composition varies across laboratories.

ImplicationPanel gene content affects detection rates, residual risk calculations, and clinical interpretation requirements.

Second‑Degree Relative

DefinitionIncludes half‑siblings, aunts, uncles, grandparents, grandchildren, and nieces/nephews (Second‑Degree Relatives).

Role in criteriaAffected first‑ or second‑degree relatives can qualify an individual for intermediate‑sized panels (up to 15 genes) under state criteria.

ReferenceDefined per NCCN (2024) in policy definitions.

At‑risk couples (ARCs)

DefinitionCouples in which both partners are carriers of pathogenic variants in the same autosomal recessive gene or where a partner is a carrier of an X‑linked pathogenic variant that places a pregnancy at risk.

SignificanceIdentification of ARCs enables reproductive options counseling and targeted prenatal or preimplantation testing.

DetectionPanel composition and detection methods determine the proportion of ARCs identified; larger panels detect more ARCs but may be unproven if ≥16 genes per policy.

Panel detection rate (DR) / recurrence risk (RR)

DefinitionMetrics (detection rate and recurrence risk) derived from allele frequencies and variant detection methods to estimate how many carriers and affected pregnancies a panel will detect.

DeterminantsDepends on carrier frequency in the population, number of genes on the panel, and laboratory detection methods (targeted genotyping vs NGS).

UseUsed to compare expected carriers and at‑risk couples detected by different panel sizes (e.g., 37‑condition vs 176‑condition panels).

Expanded Carrier Screening (ECS)

DefinitionMultigene carrier testing panels that interrogate numerous autosomal recessive and X‑linked genes; examples include panels of 94 severe/profound conditions or 110 genes used in cited studies.

Typical sizes citedStudies reference panels of 94 severe/profound conditions (example) and commercial panels ranging from 44 to over 2,000 genes.

PurposeIntended to identify reproductive carrier status irrespective of self‑reported ethnicity and to increase detection of carriers and ARCs.

ACMG Tier system

OverviewA tiered approach to carrier screening recommended by ACMG grouping conditions by carrier frequency and inclusion of CF and SMA.

Tier 1Cystic Fibrosis (CF) + Spinal Muscular Atrophy (SMA) + risk‑based screening.

Tier 2Conditions with carrier frequency ≥1/100 (includes Tier 1).

Tier 3Conditions with carrier frequency ≥1/200 (includes Tier 2 and X‑linked conditions); recommended to be offered to all pregnant/planning patients.

Tier 4Conditions with carrier frequency <1/200; considered only for consanguinity or specific family/personal history.